Blood lipid metabolic biomarkers are emerging as significant prognostic indicators for survival in cancer patients.
Level 3 - non-randomized controlled study
Systematic review and meta-analysis of observational prognostic studies
PubMed 39695484 · doi:10.1186/s12885-024-13265-8
What was done
A systematic review and meta-analysis (PROSPERO CRD42023458597) was conducted to evaluate the prognostic value of blood lipids (HDL-C, LDL-C, total cholesterol, triglycerides, ApoA1, and ApoB) for overall survival (OS) and disease-free survival (DFS) in cancer patients across 156 studies involving 85,173 patients.
What was found
Elevated levels of HDL-C, total cholesterol, and ApoA1 were significantly associated with improved OS and DFS in cancer patients. No significant relationships were identified between LDL-C, triglycerides, or ApoB levels and OS or DFS. The abstract reports no exact numerical hazard ratios, confidence intervals, or p-values.
Why it matters
This meta-analysis synthesizes broad evidence indicating that routine lipid panel markers, particularly HDL-C, total cholesterol, and ApoA1, correlate positively with survival outcomes across cancer populations.
Limits
The abstract omits all numerical effect sizes, confidence intervals, and measures of between-study heterogeneity. The findings pool heterogeneous cancer types, stages, and treatments without reporting subgroup distinctions, and observational lipid measurements are vulnerable to confounding by nutritional status, cachexia, and systemic inflammation.
Cited by
- partial Low LDL cholesterol levels in cancer patients are associated with faster cancer progression.